Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-CKD: Dapagliflozin for Renal Protection After CAG/PCI in CKD
NCT05225077Phase 4Unknown
- Sponsor
- Dong-A University
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in contrast-induced nephropathy (CIN), sponsored by Dong-A University. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT05225077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225077.